Abbott Labs shares fall as earnings beat offset by Exact Sciences acquisition drag
Abbott Laboratories shares fell 3.2% despite marginally beating Wall Street's profit and revenue estimates for the first quarter. The decline was largely due to a lowered 2026 earnings outlook, impacted by the recently completed $23 billion acquisition of Exact Sciences for oncology diagnostics. While the acquisition establishes Abbott as a leader in a high-growth segment, it is expected to dilute near-term earnings by about $0.20 per share.
https://www.proactiveinvestors.com/companies/news/1090692/abbott-labs-shares-fall-as-earnings-beat-offset-by-exact-sciences-acquisition-drag-1090692.html